0.50
+0.0172(+3.58%)
Currency In USD
| Previous Close | 0.48 |
| Open | 0.51 |
| Day High | 0.51 |
| Day Low | 0.46 |
| 52-Week High | 4.9 |
| 52-Week Low | 0.35 |
| Volume | 307,397 |
| Average Volume | 1.19M |
| Market Cap | 16.71M |
| PE | -0.17 |
| EPS | -2.97 |
| Moving Average 50 Days | 0.75 |
| Moving Average 200 Days | 1.24 |
| Change | 0.02 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $5.08 as of April 25, 2025 at a share price of $0.497. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $5.01 as of April 25, 2025 at a share price of $0.497.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of it
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
GlobeNewswire Inc.
Apr 22, 2025 12:00 PM GMT
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
GlobeNewswire Inc.
Apr 17, 2025 12:00 PM GMT
SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administrati